Biomimedica® Announces the Closing of its Oversubscribed Series B Financing (press release)
Biomimedica®, Incorporated (www.biomimedica.com), a medical device start-up company focused on the development and commercialization of its proprietary GRADION™ Total Cartilage Replacement™ (“TCR™”) technology, announced today that it has closed its Series-B financing, raising $11.9 million from a combination of new and existing investors, including conversion of approximately $2.8 million in bridge loans. Participants in this round include new investors Troika Ventures (Russia) and Biedermann Motech (Germany), together with existing investors Emergent Medical Partners (Portola Valley, CA) and Asset Management Ventures (Palo Alto, CA). Troika Ventures acted as lead investor in this round.
Artyom Yukhin, Managing Partner of Troika Ventures, commented: “Biomimedica’s technology is designed to treat a variety of cartilage defects, including osteoarthritis affecting the entire joint. This unique approach is intended to maximize the preservation of natural bone and restore the natural function of cartilage, with the goal of allowing patients to return to their normal lifestyle. We believe...
